Altogether, these data confirm CBX4 and YAP1 as two targets of sorafenib resistance and indicated a key role in maintaining the CSC properties of HCC; this activity is illustrated in Fig. 6h. The gene discussed is YAP1; the disease is hepatocellular carcinoma.